Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT

Viatris Inc. (NASDAQ:VTRS) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on June 30, Goldman Sachs reiterated a Hold rating on Viatris Inc. (NASDAQ:VTRS) with a price target of $10.00.

Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now

A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient.

The company reported $3.3 billion in total revenues in fiscal Q1 2025, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis as compared to the same period last year. This drop was primarily attributed to the negative Indore Impact.

Management stated that if the Indore Impact is excluded, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to fiscal Q1 2024.

Viatris Inc. (NASDAQ:VTRS) also generated around $67 million in new product revenues in fiscal Q1 2025, and expects to deliver new product revenues in 2025 in the $450 million to $550 million range.

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that provides healthcare and pharmaceutical products. The company’s medicines and treatments span various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women’s healthcare. Its operations are divided into the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

While we acknowledge the potential of VTRS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.